

Item 8.01 Other Events

On May 4, 2016, the Company issued a press release announcing the closing of its previously announced public offering, including the full exercise of the underwriters' option to purchase additional ordinary shares, a copy of which press release is filed as an exhibit to and incorporated by reference into this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit

No. Title of Document

99.1 Press release dated May 4, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THERAVANCE BIOPHARMA, INC.

Date: May 4, 2016 /s/ Renee D. Gala
Renee D. Gala
Senior Vice President and
Chief Financial Officer

EXHIBIT INDEX

Exhibit

No. Title of Document

99.1 Press release dated May 4, 2016.
